Alprostadil for erectile dysfunction is available in U.S.-labeled prescription injection presentations, including Caverject, Caverject Impulse and Edex. These products are not oral ED tablets. Access begins with a clinician assessing the condition and the risks of injection therapy, selecting the actual product and evaluating the initial response under professional supervision. Dispensing a package is not a substitute for confirming the correct presentation, training and follow-up plan.
The three named presentations all contain alprostadil but differ materially in their equipment and instructions. Caverject comes as powder in vials with separately required preparation supplies. Caverject Impulse has powder and diluent in a prefilled dual-chamber syringe. Edex uses single-dose, dual-chamber cartridges with a dedicated reusable Edex device. Their components, storage directions and preparation systems must not be assumed interchangeable merely because the ingredient is the same.
This page covers the U.S. prescription, in-office assessment, training and pharmacy-fulfillment path rather than giving procedural injection instructions or selecting a dose. Approval and product labeling do not establish live stock. For wider treatment context, see ED treatment modalities and oral sildenafil versus injection treatment.
The first stage is clinical evaluation of erectile dysfunction and whether injection treatment is appropriate. The clinician should review cardiovascular conditions, penile health, medications, bleeding concerns, prior priapism and the patient's capacity for correct supervised learning. A prescription and supervised treatment plan follow only if the clinician considers the modality suitable.
When a product is chosen, the pharmacy must dispense the exact approved presentation and its authorized components. Later home use is conditional on office assessment and training; an online storefront promising a complete injection regimen without a supervising clinician is not a valid substitute.
| Stage | What to confirm | Why it matters |
|---|---|---|
| Medical eligibility | Urology or qualified clinical evaluation and full health history | Injection treatment has route-specific contraindications |
| First response assessment | Initial office administration and supervised evaluation | Helps define clinical suitability and limits risk |
| Approved product | Caverject vial, Caverject Impulse dual-chamber syringe or Edex cartridge/device; exact presentation and components | These are distinct systems with separate labeling and equipment requirements |
| Patient training | Competency confirmed by treating professional | Safe home use depends on product-specific instruction |
| Licensed pharmacy | State license, prescription verification, pharmacist access | Protects against unapproved or counterfeit products |
| Ongoing care | Follow-up, monitoring for tissue changes and emergency plan | Protects against prolonged erections and fibrosis |
Caverject is a U.S.-labeled alprostadil powder for intracavernosal injection supplied in vials. Its labeling distinguishes the medicine from preparation supplies that are not necessarily inside the medicine package, such as the prescribed diluent, needles and syringes. The pharmacist and treating clinic should confirm the exact vial presentation and required supplied or separately obtained components. Never infer that a vial purchase includes a complete injection kit or use a different product's preparation instructions.
A medicine-only quote and a procedure-ready supply list are not the same thing. Before home treatment, the patient and pharmacy should reconcile the clinician's written plan, dispensed product, permitted components and training records. Packaging differences or missing supplies are reasons to contact the pharmacist or prescriber, not reasons to improvise a preparation.
Caverject Impulse has a distinct U.S. label and approved application from vial-based Caverject. It supplies lyophilized alprostadil and diluent in a prefilled dual-chamber syringe system, with product-specific accessories. The word Impulse therefore has a practical meaning: the dispenser must confirm that the written prescription, packaged system and clinician training all refer to the same presentation, rather than interpreting the two Caverject names as identical kits.
This distinction also matters when requesting a complete quote, arranging replacement components or checking shipment damage. A Caverject vial preparation, a Caverject Impulse syringe and an Edex cartridge cannot be treated as interchangeable equipment. The pharmacy should verify the actual FDA-labeled item and the clinic should provide any device-specific instruction in person, without reliance on a different product's packaging insert.
Edex is also FDA-labeled alprostadil for intracavernosal use, supplied in single-dose, dual-chamber cartridges for a reusable Edex injection device. Its cartridge packs are designed around the specified device and accompanying consumables. Its label describes product-specific preparation and administration, but those procedures should be taught and assessed by the treating clinical team, not reconstructed from this purchasing guide.
The clinic and pharmacy should check whether the ordered Edex cartridge pack includes the dedicated reusable device and which compatible supplies are present. A Caverject vial or Impulse syringe is not a replacement cartridge for that system. If an existing patient already owns an Edex device, the team must still check the exact approved cartridge and package ordered; equipment questions should be settled before treatment.
Caverject, Caverject Impulse and Edex labeling require initial treatment evaluation under professional supervision, with product-specific instruction and assessment before home administration. The goal is to determine an acceptable response while minimizing excessive duration, local injury and confusion about how to handle a sterile product. Edex similarly demands product-specific training and monitoring.
The clinic should explain who conducts training, how competency is assessed, which follow-up visit is expected and when a patient should contact the team. A patient should not begin simply because medication was shipped to their address. This article intentionally includes no injection site, needle-angle or mixing instructions.
Injection therapy may be inappropriate for people with conditions that predispose to priapism, certain penile anatomical deformities or fibrosis, penile implants, or other contraindications listed for the chosen product. Potential bleeding concerns and concomitant medicines should also be discussed. A complete medical assessment matters even when the injection is local rather than swallowed.
Relevant warning symptoms include persistent erection, substantial local pain or bleeding and new penile curvature or tissue changes. The clinician should give a written plan for concerns and follow-up. No consumer should improvise an injection quantity or frequency on the assumption that an extra amount will reliably help.
Caverject and Edex product information emphasizes prolonged erection and priapism. An erection lasting more than four hours is an emergency requiring immediate medical assistance to reduce the risk of permanent damage. This instruction is more important than whether a patient thinks the erection is painful or whether they have a later clinic appointment.
Repeated injection therapy also requires monitoring for penile fibrosis or anatomical changes. A new curve, palpable change or repeated discomfort should be reported to the treating professional. The response is not to skip clinical supervision or add an oral PDE5 medicine in an attempt to correct the problem.
Verify the pharmacy's state-board license, its U.S. contact information and access to a licensed pharmacist, particularly if the fill is shipped. The pharmacy should validate the prescription and identify the exact U.S.-approved presentation, labeler, packaging and accompanying product materials. Mere use of a Caverject or Edex logo on a website is not proof of legitimacy.
FDA BeSafeRx guidance warns against sellers dispensing prescription medicine without an appropriate prescription or license. Do not assume that a marketplace listing, import service or mail-order affiliate is a licensed dispensing pharmacy. Use clinical and pharmacy identifiers independently rather than trusting testimonials. ED telehealth models can help explain the distinction between clinical evaluation and lawful dispensing, but no virtual provider can replace required supervised initiation and hands-on training.
Approved alprostadil injection presentations have specific storage and post-preparation handling instructions that depend on the product. The patient should receive the exact label and product-specific counseling and confirm whether transport conditions, expiry or a damaged package affect suitability. These details cannot safely be copied from one injection brand to another.
When receiving an order, inspect the sealed package and pharmacy label for the right patient, product, strength and components. If there is evidence of tampering, an expired product, incorrect device or a packaging discrepancy, contact the licensed pharmacist before using the medicine; do not attempt improvised sterile handling.
MUSE was a urethral alprostadil product, not an intracavernosal injection. Its U.S. branded presentations appear in the discontinued-products section of the FDA Orange Book, so old product listings should not be interpreted as an offer of current supply. Its route and applicator do not substitute for prescribed Caverject, Caverject Impulse or Edex. A valid prescription must identify the intended route and product.
Compounded multi-drug injection mixtures, sometimes discussed in ED forums, are also distinct from the FDA-approved single-ingredient Caverject and Edex products. The FDA does not approve individual compounded preparations in the same way as approved brand products. This page does not recommend switching to mixtures or provide their preparation steps.
The ED medication cost comparison highlights that injection access can involve several separate charges: the medication and prescribed kit, required device or consumable supplies, professional consultation and training, follow-up and possible delivery. Ask the dispensing pharmacy and clinic to clarify which services are included and which are billed separately. A medicine-only quote can omit important costs of the pathway.
If insurance is involved, confirm whether the exact product, device, clinician visits or pharmacy are covered and whether prior authorization is necessary. If self-paying, request a current, complete and itemized amount before deciding. Do not infer costs from outdated retail examples or unverified coupon claims.
Before home treatment, the patient should know which clinical team to contact about missed training, kit questions, inadequate response or unexpected symptoms and should have clear emergency instructions. Responsible dispensing includes access to pharmacy counseling; responsible prescribing includes clinical follow-up and monitoring for tissue changes.
The central decision is not simply where to buy alprostadil but how to obtain the correct approved product within a supervised care plan. Readers still considering an oral option can review tadalafil versus injections and vardenafil versus injections, without treating either comparison as a recommendation to combine medicines. A legitimate prescription, the exact vial, syringe or cartridge presentation with required components, product-specific training and an emergency plan are all essential.
No. They are prescription products. A qualified clinician must determine suitability and supervise the initial injection treatment assessment.
Yes. Product labeling calls for supervised initiation and verified training before permitted use outside the clinical setting.
No automatic interchangeability should be assumed. Caverject uses vials, Caverject Impulse a dual-chamber syringe, and Edex dedicated cartridges and a reusable device; a clinician and pharmacist must confirm the prescribed system.
No. Edex is an intracavernosal alprostadil injection product, not a PDE5 inhibitor tablet.
Contact the dispensing pharmacist and treating clinician before use. Do not borrow components or substitute procedures from another product.
Seek immediate emergency medical care. Delayed treatment of priapism can cause permanent erectile tissue damage.
No. It uses a different route and product system, and historical labeling does not prove current supply.
Coverage varies. Ask the insurer, prescribing clinic and pharmacy to verify medication, device, supplies, training and additional fees before proceeding.